Ocugen, a biotech leader in gene therapies for blindness, announced it will showcase its innovative modifier gene therapy platform at several investor and industry conferences in July 2026. Presentations will cover clinical trial results and regenerative approaches for retinal diseases, highlighting Ocugen's gene-agnostic therapy targeting complex blindness conditions. These events aim to update investors and the medical community on Ocugen's progress and future plans in treating inherited retinal diseases and age-related macular degeneration. Webcasts and replays will be available for wider access.
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against BitGo Holdings, ADMA Biologics, and Erasca. The lawsuits allege these companies made false or misleading statements affe...
Ocular Therapeutix announced its participation in multiple scientific and investor conferences in July 2026, including presentations on its investigational retinal drug AXPAXLI and real-world data on anti-VEGF treatments. Key events include the OIS R...
Step Pharma has appointed Neil J. Gallagher, MD, PhD, as a Non-Executive Director to strengthen its board as it advances dencatistat, a first-in-class CTPS1 inhibitor targeting essential thrombocythaemia, lymphoma, and solid tumours. Gallagher brings...
Gaming and Leisure Properties, Inc. announced it will release its second quarter 2026 financial results after market close on July 30, 2026. The company will hold a conference call on July 31, 2026, at 10:00 a.m. ET to discuss the results and recent ...
GlobalFoundries announced it will hold a conference call on August 5, 2026, at 8:30 a.m. ET to discuss its second quarter 2026 financial results. Investors and interested parties can join the call by registering online, and the webcast will be availa...
